| BNF |
British National Formulary |
| COPD |
chronic obstructive airway disease |
| COVID-19 |
coronavirus disease 2019 |
| Il-6 |
interleukin 6 |
| IV |
intravenous |
| mg |
milligram |
| MHRA |
Medicines & Healthcare products Regulatory Agency |
| ml |
millilitre |
| mmol/l |
millimole per litre |
| NG |
nasogastric |
| NHSL |
National Health Service Lothian |
| nMAB |
neutralising monoclonal antibody |
| 02 |
oxygen |
| PCR |
polymerase chain reaction |
| POCT |
Point-of–care-test |
| RA |
Room air |
| RECOVERY (trial) |
Randomised evaluation of COVID-19 therapy |
| REMAP-CAP |
Randomised, Embedded, Multi-factorial, Adaptive Platform Trial for Community-Acquired Pneumonia |
| SARS-CoV-2 |
Severe acute respiratory syndrome coronavirus 2 |
| SmPC |
Summary of Product Characteristics |
| WHO |
World Health Organisation |